These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 12463417)

  • 1. Immune responses to therapeutic proteins in humans--clinical significance, assessment and prediction.
    Koren E; Zuckerman LA; Mire-Sluis AR
    Curr Pharm Biotechnol; 2002 Dec; 3(4):349-60. PubMed ID: 12463417
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictive power of preclinical studies in animals for the immunogenicity of recombinant therapeutic proteins in humans.
    Bugelski PJ; Treacy G
    Curr Opin Mol Ther; 2004 Feb; 6(1):10-6. PubMed ID: 15011776
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Challenges related to the immunogenicity of parenteral recombinant proteins: Underlying mechanisms and new approaches to overcome it.
    Faraji F; Karjoo Z; Moghaddam MV; Heidari S; Emameh RZ; Falak R
    Int Rev Immunol; 2018; 37(6):301-315. PubMed ID: 29851534
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New approaches to prediction of immune responses to therapeutic proteins during preclinical development.
    Perry LC; Jones TD; Baker MP
    Drugs R D; 2008; 9(6):385-96. PubMed ID: 18989990
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preclinical models used for immunogenicity prediction of therapeutic proteins.
    Brinks V; Weinbuch D; Baker M; Dean Y; Stas P; Kostense S; Rup B; Jiskoot W
    Pharm Res; 2013 Jul; 30(7):1719-28. PubMed ID: 23649852
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification and removal of immunogenicity in therapeutic proteins.
    Baker MP; Jones TD
    Curr Opin Drug Discov Devel; 2007 Mar; 10(2):219-27. PubMed ID: 17436557
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prediction of immunogenicity of therapeutic proteins: validity of computational tools.
    Bryson CJ; Jones TD; Baker MP
    BioDrugs; 2010 Feb; 24(1):1-8. PubMed ID: 20055528
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The prediction of immunogenicity of therapeutic proteins].
    Maillère B; Delluc S; Ravot G
    Med Sci (Paris); 2012 Jan; 28(1):82-8. PubMed ID: 22289835
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pre-clinical considerations in the assessment of immunogenicity for protein therapeutics.
    Baker M; Carr F
    Curr Drug Saf; 2010 Oct; 5(4):308-13. PubMed ID: 20615174
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Determinants of immunogenic response to protein therapeutics.
    Singh SK; Cousens LP; Alvarez D; Mahajan PB
    Biologicals; 2012 Sep; 40(5):364-8. PubMed ID: 22770604
    [TBL] [Abstract][Full Text] [Related]  

  • 11. T-cell dependent immunogenicity of protein therapeutics: Preclinical assessment and mitigation.
    Jawa V; Cousens LP; Awwad M; Wakshull E; Kropshofer H; De Groot AS
    Clin Immunol; 2013 Dec; 149(3):534-55. PubMed ID: 24263283
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunogenicity of protein therapeutics.
    De Groot AS; Scott DW
    Trends Immunol; 2007 Nov; 28(11):482-90. PubMed ID: 17964218
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EpiSweep: Computationally Driven Reengineering of Therapeutic Proteins to Reduce Immunogenicity While Maintaining Function.
    Choi Y; Verma D; Griswold KE; Bailey-Kellogg C
    Methods Mol Biol; 2017; 1529():375-398. PubMed ID: 27914063
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products.
    Mire-Sluis AR; Barrett YC; Devanarayan V; Koren E; Liu H; Maia M; Parish T; Scott G; Shankar G; Shores E; Swanson SJ; Taniguchi G; Wierda D; Zuckerman LA
    J Immunol Methods; 2004 Jun; 289(1-2):1-16. PubMed ID: 15251407
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prediction of immunogenicity: in silico paradigms, ex vivo and in vivo correlates.
    De Groot AS; McMurry J; Moise L
    Curr Opin Pharmacol; 2008 Oct; 8(5):620-6. PubMed ID: 18775515
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prediction of immunogenicity for therapeutic proteins: state of the art.
    De Groot AS; Moise L
    Curr Opin Drug Discov Devel; 2007 May; 10(3):332-40. PubMed ID: 17554860
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Minimizing the immunogenicity of protein therapeutics.
    Chirino AJ; Ary ML; Marshall SA
    Drug Discov Today; 2004 Jan; 9(2):82-90. PubMed ID: 15012932
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Approaches to Mitigate the Unwanted Immunogenicity of Therapeutic Proteins during Drug Development.
    Salazar-Fontana LI; Desai DD; Khan TA; Pillutla RC; Prior S; Ramakrishnan R; Schneider J; Joseph A
    AAPS J; 2017 Mar; 19(2):377-385. PubMed ID: 28083796
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nonclinical immunogenicity risk assessment of therapeutic proteins.
    Tourdot S; Hickling TP
    Bioanalysis; 2019 Sep; 11(17):1631-1643. PubMed ID: 31208200
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunogenicity of therapeutic proteins: clinical implications and future prospects.
    Schellekens H
    Clin Ther; 2002 Nov; 24(11):1720-40; discussion 1719. PubMed ID: 12501870
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.